Our Development Pipeline

All of our immunotherapy technologies are designed to be delivered as simple injections. We look forward to the day when treating cancer will be as simple as getting a flu shot – a better way to treat cancer.

Children’s Cancer

A disease-specific immunotherapy targeted at treating Ewing sarcoma, a rare but deadly bone and soft tissue cancer that affects children and young adults. Unfortunately, the death rate for patients with recurrent Ewing sarcoma is nearly 100%.

Universal Cancer Vaccine​ Platform (UCV)

A novel and customizable Universal Cancer Vaccine, to be delivered as a shot, that uses cutting-edge bioengineering and molecular technologies to uniquely detect, mark and kill only cancer cells. By forcing cancer cells to express a unique marker not found in healthy cells, custom antibody drugs and the body’s immune cells can target and destroy the cancer cells with precision.

Universal CAR-T Cell Platform (UCAR-T)

A novel and customizable low-cost treatment platform, to be delivered as a shot, that can reprogram natural immune T-cells inside the body to seek and destroy targeted cancer cells. These modified T-cells are called Chimeric Antigen Receptor (CAR) T Cells. Conventional CAR-T Cell therapy can cost more than $500,000 per dose due to complicated and expensive lab processes. Our goal is to lower the cost to a few thousand dollars per dose by helping the body make its own CAR T-cells.

UCV and UCAR-T can be used separately. However, when used together, we can kill cancer cells with extreme precision using the body’s immune system at very low costs. UCV detects and marks a unique target and UCAR-T makes T-cells attack that target.

Massive Market Opportunity

How big is the biotechnology market?

According to Precedence Research, the global biotechnology market is projected to grow from $1.3 trillion in 2023 to $3.2 trillion by 2030

$3.2 trillion

How big is the cancer drug development market?

According to Fortune Business Insights, the global oncology drugs market is projected to grow from $205 billion in 2023 to $484 billion by 2030.

$484 billion


Pre-clinical. We’re developing cutting edge immunotherapy cancer treatments that use the body’s immune system to fight cancer.

World-class researchers and scientists.

Our team of dedicated scientists is on the cutting edge of cancer research. From the lab to the clinic, we are committed to finding new and better ways to prevent and treat cancer.


Years of collective

Steven J. Jonas, MD/PHD

Principal Investigator

Dr. Jonas is a UCLA physician-scientist specializing in pediatric hematology/oncology. He received a bachelor’s degree in materials science & engineering and a master’s degree in biomedical engineering prior to starting his medical training to pursue his M.D. and Ph.D. degrees at UCLA through its NIH-supported Medical Scientist Training Program. He leads a multidisciplinary research team that targets the development and application of new nanotechnologies and methods to support the childhood cancer and regenerative medicine communities in accelerating the discovery of innovative gene therapy approaches.

Satiro de oliveira, MD

Principal Investigator

Watch Interview

Dr. De Oliveira is a board-certified pediatrician and board-certified pediatric hematology/oncologist. He received his medical degree in Brazil and completed his pediatric residency at Woodhull Medical and Mental Health Center in New York and his pediatric hematology/oncology fellowship at the Children’s Hospital Lost Angeles. His clinical focus is on pediatric oncology and gene therapies and his research focus is on cancer immunotherapy and biology of stem cell transplantation.

Christopher Seet, MD/phd

Principal Investigator

Dr. Seet is a hematologist and oncologist subspecializing in the treatment of hematologic malignancies, including hematopoietic stem cell transplantation, cellular therapy and clinical trials of novel therapeutics. He received a undergraduate degree in Biological Science at the University of Chicago, a medical degree at the University of Sydney, Australia and PhD in Cellular and Molecular Pathology at UCLA. His research focuses on human T cell and dendritic cell tumor immunology, and the development of engineered stem cell-based approaches to cancer therapy.

Noah Federman, MD

Principal Investigator

Dr. Federman is the Director of the Pediatric Bone and Soft Tissue Sarcoma Program at UCLA. He specializes in treating children, adolescents and young adults with these aggressive cancers. He runs a multidisciplinary program involving pediatric and medical oncologists, radiation oncologists, orthopedic oncology surgeons, musculoskeletal radiologists and pathologists, nuclear medicine specialists, physical therapists and prosthetic specialists. He received a medical degree from the Icahn School of Medicine at Mount Sinai and completed his residency and fellowship at UCLA.

Christopher Denny, MD

Project Advisor

Dr. Denny has served as a physician at UCLA for over 3 decades primarily focused on pediatric oncology. He has trained and mentored some of UCLA’s best and brightest scientists and doctors in the field. Dr. Denny received a bachelor’s degree from University of Pennsylvania and a medical degree from the University of Pennsylvania School of Medicine. He completed his residency at the Children’s National Medical Center and fellowship at the National Institutes of Health Clinical Center. Most of Dr. Denny’s academic success has come through applying basic molecular biology tools to seek molecular mechanisms for what he witnesses when treating pediatric hematology/oncology patients.




November 2, 2023 - Ezra Cohen Tempus Labs


October 2, 2023 - CancerVAX CEO Discusses Expanded Pipeline at UCLA


August 14, 2023 - Steven Jonas - UCLA


June 28, 2023 - Lara Sullivan - Pyxis Oncology

News Highlights

November 2, 2023

CancerVAX CEO Ryan Davies Discusses Cancer Drug Development with Dr. Ezra Cohen

CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that uses the body’s immune system to fight cancer, today announced that in a recent Company podcast its CEO, Ryan Davies, and Tempus Labs Chief Medical Officer for Oncology Dr. Ezra Cohen, discussed his time at Tempus Labs, Moores Cancer Center and University of Chicago

September 12, 2023

CancerVAX Expands Development Pipeline to Include a Universal CAR-T Cell Platform

CancerVAX, Inc., a pre-clinical biotechnology company working with UCLA to develop breakthrough immunotherapy cancer treatments that use the body’s immune system to fight cancer, today announced an expansion of its development pipeline to include a Universal CAR-T Cell Platform that can dramatically lower the cost of CAR-T cell cancer therapies

August 24, 2023

CancerVAX CEO Ryan Davies Discussed Cancer Immunotherapy with UCLA Physician-Scientist

CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that uses the body’s immune system to fight cancer, today announced that in a recent Company podcast its CEO, Ryan Davies, spoke with and UCLA cancer physician and researcher, Dr. Steven Jonas, about his journey to becoming both a practicing cancer doctor and active cancer researcher

July 25, 2023

World Renowned Biomedical Professor Jonathan Lakey Joins CancerVAX Board of Advisors

Dr. Lakey has been recognized nationally and internationally for his groundbreaking research in cell and tissue transplantation for patients suffering from diabetes and cancer